Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 13Prostatic Neoplasms 9Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Endometrial Neoplasms 3Colorectal Neoplasms 3Cardiovascular Diseases 3Cardiotoxicity 3Triple Negative Breast Neoplasms 2Polycystic Ovary Syndrome 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Kidney Neoplasms 2Heart Failure 2Endometrial Hyperplasia 2Carcinoma, Renal Cell 2Waldenstrom Macroglobulinemia 1Venous Thrombosis 1Urogenital Neoplasms 1Smoking 1Sarcoma 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Pancreatic Neoplasms 1Overall Survival 1Ototoxicity 1

Interventions

evolocumab 1Ezetimibe 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hyperlipoproteinemia Type II × Atorvastatin × Clear all
NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

CHU de Quebec-Universite Laval

Phase EARLY_PHASE1 Active not recruiting
3 enrolled
Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡